Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation
AffiliationUniv Arizona, Internal Med
chronic idiopathic constipation
clinical efficacy of prucalopride
safety profile of prucalopride
MetadataShow full item record
CitationTameez Ud Din A, Khan A H, Bajwa H, et al. (April 04, 2019) Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation. Cureus 11(4): e4382. doi:10.7759/cureus.4382
Rights© Copyright 2019 Tameez Ud Din et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractChronic idiopathic constipation (CIC) can be defined as bowel movements that are difficult to pass, are not occurring frequently, or have incomplete evacuation during defecation. A high-fiber diet and laxatives are the commonly used treatments, but in many cases, they do not produce satisfactory results. The first line of treatment is osmotic laxatives. If there is no improvement, the second line is guanylate cyclase-C (GCC) agonists like linaclotide or prokinetic agents such as prucalopride. On December 14, 2018, the United States Food and Drug Administration (US FDA) approved prucalopride for treating chronic idiopathic constipation. Prucalopride is a prokinetic agent which works at the 5-hydroxytryptamine receptor 4 (5-HT4) as an agonist with greater receptor selectivity. Patients on prucalopride reported improved symptoms, quality of life and satisfaction. The most frequent adverse events were headaches and problems related to the gastrointestinal tract. Caution should be taken when using prucalopride in patients with impaired liver and renal function. In Canada, prucalopride has been approved for treatment of female patients with chronic idiopathic constipation who have failed therapy with at least two laxatives from different classes over a six-month period.
NoteOpen access journal
VersionFinal published version